Treatment of premenopausal patients with advanced or recurrent breast cancer by chemical ablation / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
;
(6): 60-62, 2003.
Article
in Chinese
| WPRIM
| ID: wpr-301898
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the clinical efficacy and safety of luteinizing hormone releasing hormone (LH-RH) analog in premenopausal patients with advanced or recurrent breast cancer.</p><p><b>METHODS</b>LH-RH analog (enantone 3.75 mg/2 ml) were administered to 28 premenopausal patients with advanced recurrent breast cancer and its efficacy and side effect were observed.</p><p><b>RESULTS</b>The response rate (complete response and partial response) was 42.9%, and after 8 weeks of treatment, the plasma estrogen in all patients decreased to the level of postmenopause. No major adverse events were observed.</p><p><b>CONCLUSIONS</b>LH-RH analog is effective and safe for premenopausal breast cancer with low adverse reaction and its administration method is easy.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Blood
/
Breast Neoplasms
/
Luteinizing Hormone
/
Gonadotropin-Releasing Hormone
/
Leuprolide
/
Premenopause
/
Therapeutic Uses
/
Drug Therapy
/
Estrogens
/
Neoplasm Recurrence, Local
Limits:
Adult
/
Female
/
Humans
Language:
Chinese
Journal:
Acta Academiae Medicinae Sinicae
Year:
2003
Type:
Article
Similar
MEDLINE
...
LILACS
LIS